We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
Read MoreHide Full Article
Amedisys, Inc. (AMED - Free Report) reported adjusted earnings per share (EPS) of 94 cents in fourth-quarter 2019, up 3.3% from the year-ago figure. The bottom line also beat the Zacks Consensus Estimate of 93 cents by 1.1%.
Net service revenues grossed $500.7 million, up 15.3% year over year. However, the top line missed the Zacks Consensus Estimate by 1.8%.
2019 at a Glance
In 2019, the company reported net service revenues worth $1.96 billion, which improved 17.9% from the previous year. The top line missed the Zacks Consensus Estimate by 0.5%.
Adjusted EPS for the year was $4.40, up 21.2% from that of 2018. The figure also beat the consensus mark by 0.2%.
Within the company's Home Health division, net service revenues totaled $316.2 million in the quarter, reflecting a 4% improvement year over year. Moreover, Medicare revenues of $215.2 million inched up 1.7% year over year. Non-Medicare revenues improved 9.2% to $101 million.
Within the Hospice division, net service revenues were $164.6 million (up 51.3% year over year) including Medicare revenues of $156.6 million (up 51.3%) and non-Medicare revenues of $8 million (up 50.9%).
The company recently integrated two additional operating segments within its business, namely, Personal Care and Corporate. At Personal Care, net service revenues totaled $19.9 million, representing a decline of 7.9% from the year-ago number. Meanwhile, the Corporate segment did not register any revenues in the fourth quarter.
Margins
Gross margin expanded 133 basis points (bps) to 40.9% in the quarter under review. Further, expense on salaries and benefits advanced 20.2% to $101.3 million. Other expenses increased 12.6% to $48.2 million as well. Meanwhile, operating profit of $41.6 million reflects a 14.1% rise from the year-ago figure. Operating margin also contracted 10 bps to 8.3% from the prior-year level.
Cash Position
Amedisys exited the December quarter with cash and cash equivalents of $30.3 million compared with $20.2 million in the prior-year quarter. The company's long-term obligations (excluding current portion) were $232.3 million at the end of the fourth quarter compared with $5.8 million in the year-ago quarter.
At the end of 2019, net cash provided by operating activities was $202 million compared with $223.5 million at the end of 2018.
2020 Guidance
Net service revenues are projected to range between $2.12 billion and $2.16 billion. Adjusted EPS is expected to be in the band of $4.90-$5.13 (on the basis of an anticipated 33.4 million shares outstanding).
Adjusted EBITDA is estimated to be in the range of $250-$260 million.
Our Take
Amedisys ended the fourth quarter on a mixed note. At the Home Health and Hospice divisions, the company witnessed solid year-over-year growth in Medicare and non-Medicare revenues. Amedisys is currently exploring opportunities in these segments. We are also impressed by the company’s solid performance in the recently-launched Personal Care segment. A favorable demographic trend and strategic acquisitions also bode well.
However, an intense competitive landscape and regulatory concerns pose challenges to the home health and hospice industry. Escalating costs and expenses remain woes.
Zacks Rank
Currently, Amedisys carries a Zacks Rank #3 (Hold).
Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
Amedisys, Inc. (AMED - Free Report) reported adjusted earnings per share (EPS) of 94 cents in fourth-quarter 2019, up 3.3% from the year-ago figure. The bottom line also beat the Zacks Consensus Estimate of 93 cents by 1.1%.
Net service revenues grossed $500.7 million, up 15.3% year over year. However, the top line missed the Zacks Consensus Estimate by 1.8%.
2019 at a Glance
In 2019, the company reported net service revenues worth $1.96 billion, which improved 17.9% from the previous year. The top line missed the Zacks Consensus Estimate by 0.5%.
Adjusted EPS for the year was $4.40, up 21.2% from that of 2018. The figure also beat the consensus mark by 0.2%.
Amedisys, Inc. Price, Consensus and EPS Surprise
Amedisys, Inc. price-consensus-eps-surprise-chart | Amedisys, Inc. Quote
Quarter in Detail
Within the company's Home Health division, net service revenues totaled $316.2 million in the quarter, reflecting a 4% improvement year over year. Moreover, Medicare revenues of $215.2 million inched up 1.7% year over year. Non-Medicare revenues improved 9.2% to $101 million.
Within the Hospice division, net service revenues were $164.6 million (up 51.3% year over year) including Medicare revenues of $156.6 million (up 51.3%) and non-Medicare revenues of $8 million (up 50.9%).
The company recently integrated two additional operating segments within its business, namely, Personal Care and Corporate. At Personal Care, net service revenues totaled $19.9 million, representing a decline of 7.9% from the year-ago number. Meanwhile, the Corporate segment did not register any revenues in the fourth quarter.
Margins
Gross margin expanded 133 basis points (bps) to 40.9% in the quarter under review. Further, expense on salaries and benefits advanced 20.2% to $101.3 million. Other expenses increased 12.6% to $48.2 million as well. Meanwhile, operating profit of $41.6 million reflects a 14.1% rise from the year-ago figure. Operating margin also contracted 10 bps to 8.3% from the prior-year level.
Cash Position
Amedisys exited the December quarter with cash and cash equivalents of $30.3 million compared with $20.2 million in the prior-year quarter. The company's long-term obligations (excluding current portion) were $232.3 million at the end of the fourth quarter compared with $5.8 million in the year-ago quarter.
At the end of 2019, net cash provided by operating activities was $202 million compared with $223.5 million at the end of 2018.
2020 Guidance
Net service revenues are projected to range between $2.12 billion and $2.16 billion.
Adjusted EPS is expected to be in the band of $4.90-$5.13 (on the basis of an anticipated 33.4 million shares outstanding).
Adjusted EBITDA is estimated to be in the range of $250-$260 million.
Our Take
Amedisys ended the fourth quarter on a mixed note. At the Home Health and Hospice divisions, the company witnessed solid year-over-year growth in Medicare and non-Medicare revenues. Amedisys is currently exploring opportunities in these segments. We are also impressed by the company’s solid performance in the recently-launched Personal Care segment. A favorable demographic trend and strategic acquisitions also bode well.
However, an intense competitive landscape and regulatory concerns pose challenges to the home health and hospice industry. Escalating costs and expenses remain woes.
Zacks Rank
Currently, Amedisys carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks — which reported solid results this earnings season — include Stryker Corporation (SYK - Free Report) , Accuray Incorporated (ARAY - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>